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Abstract 
Objectives: To evaluate the use of H-FABP as a novel marker in early detection of cardiac damage (MI) in 
patients presenting with symptoms of the acute coronary syndrome (ACS). 
Methods: This cross-sectional study included 250 subjects; 125 patients of ACS presenting within four hours of 
the onset of chest pain and/dyspnea and 125 age and sex-matched healthy controls. An initial blood sample was 
taken from patients at presentation. Blood samples of healthy control subjects were also taken. The blood samples 
of both groups were centrifuged and stored at -200 C for H-FABP analysis. All the patients and control subjects 
were thoroughly examined and detailed history was taken. The diagnostic test was troponin-T.H-FABP 
concentrations of all samples were measured by ELISA-kit. The results were analyzed statistically. A p-value≤0.05 
was considered statistically significant. 
Results: In 125 patients of ACS, H-FABP showed a sensitivity of 85% and specificity of 83.3% for acute MI 
diagnosis at a cut-off level of 16 ng/ml. Positive predictive values and negative predictive values were 96.8% and 
48.4% respectively. The accuracy was 84.4%and the area under the ROC curve was 0.842. 
Conclusion: Evaluation of heart-type fatty acid-binding Protein (H-FABP) within four hours of onset ACS 
symptoms may be a valuable tool in the diagnosis of AMI. 
Keywords: Heart-type fatty acid-binding protein, Acute coronary syndrome, Myocardial infarction. 
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Introduction 
 
Cardiovascular disease (CVD) has emerged as a 
serious health issue and according to recent statistics, 
it almost contributes to one in every three deaths 
globally and this number will surely rise in both 
under-developed and developed countries.1 The 
inhabitants of Indo-Asian origin have a huge burden 
of coronary artery disease (CAD) which is the leading 
cause of death in the Indo-Pakistan subcontinent.2 The 
incidence of ischemic heart disease (IHD) is increasing 
in Pakistan and one in every four individuals with age 
≥ 40 years may be having underlying coronary artery 
disease in urban areas of Pakistan.3 Inflammation is 
increased in case of risk factors and their reduction, 
elimination or treatment may result in slowing 
inflammation and decreasing the threat of MI.4 
ACS refers to a group of clinical diseases as a result of 
acute myocardial ischemia and includes unstable 
angina (UA), non-ST-segment elevation myocardial 
infarction (NSTEMI), and ST-segment elevation 
myocardial infarction (STEMI).5 The annual incidence 
of NSTEMI has increased compared to STEMI as it is 
difficult to diagnose and hence to manage effectively.6 
Also, it has been seen that a 12-lead ECG has low 
sensitivity and specificity for the diagnosis of coronary 
artery ischemia and has shown a range of accuracy 
from 58.5% to 62% in identifying ACS. 7 In such clinical 
situations cardiac biomarkers play a critical role for 
diagnosis, risk assessment and disease management 
Currently, cardiac troponins (T or I) are the preferred 
biomarkers  to establish the diagnosis of acute MI.8 
But a major limitation of this current protocol is that 
troponin levels do not raise to a detectable level until 
six hours after the start of symptoms.9 It has also been 
observed that patients with NSTEMI at high risk will 
benefit from earlier revascularization if it is done 
within four hours of the onset of occluding coronary 
thrombus but unfortunately, troponins do not confirm 
NSTEMI due to their low sensitivity within initial four 
hours.10 There has been a great interest in seeking 
alternative or additional markers which could detect 
cardiac damage earlier.11 Heart-type fatty acid-binding 
protein (H-FABP) may have the potential to fulfill the 
requirement.12 After the damage to cardiomyocytes, it 
is quickly released in the blood from injured 
myocardium, detectable within 20 minutes of 
myocardial injury, reaches to the maximum level in 
three-four  hours and   comes to basal level within 
twenty-four hours due to rapid renal excretion.13 
H-FABP is a low molecular weight membrane-bound 
protein present in high concentration in heart tissues 
and carries out transportation of insoluble long-chain 
fatty acids (LCFA) from the blood into the 
cardiomyocytes for energy. Due to cardiac cell injury, 
it appears in circulation even earlier than troponin.14 
Due to its rapid release and early detection in the 
blood there has been a great interest in its utility as an 
early indicator of MI.15 It been found that H-FABP can 
detect early cardiac damage within three hours of 
symptoms onset and can rule out non-ischemic acute 
chest pain.16 
The major issue of H-FABP availability to use it in 
routine testing is that its assay has not been 
standardized and the validity of effectiveness of this 
assay has not been established so far.17 
 
Materials and Methods  
 
This analytical cross-sectional study was carried out at 
the emergency department (ED) of Punjab Institute of 
Cardiology (PIC) Lahore from November 2014 to 
January 2015. The study was approved by the ethical 
committee of the Postgraduate Medical Institute 
Lahore and was conducted after approval of the head 
of institute PIC Lahore. 
The sample size was calculated using the formula 
n=Z21-α/2 x SN x (1-SN)/ L2×prevalence. 
The calculated sample size was 492 (246 patients and 
246 healthy control subjects) but due to limited 
resources, the sample size was reduced and we finally 
included 250 subjects of both sexes. Among 250 
subjects, 125 were patients showing symptoms of ACS 
presenting to the ED with the final diagnosis of ACS 
established by the expert panel of doctors and 125 
were healthy age and sex-matched blood donors as 
controls. 
The inclusion criteria for patients were Age ≥ 40 years 
with typical chest pain and/or dyspnea suggestive of 
ischemic origin within 4hours of onset and had the 
final diagnosis of ACS. The exclusion criteria were 
patients who had undergone an intervention or 
received fibrinolytic therapy at an early stage and 
those with serum creatinine level ≥1.3 mg/dl  
The control group had no history or clinical findings of 
cardiac or other systemic diseases. Informed written 
consent was obtained from all the participants. The 
values of cardiac biomarkers (Troponin-T, CK-MB, 
and H-FABP), creatinine and other routine 
investigations were also documented in the Performa. 
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At a presentation in ED, three ml of the blood was 
drawn from each patient and stored for H-FABP 
estimation as per the recommendation of the 
manufacturer. Blood for routine investigation was also 
taken. Another blood sample was drawn from each 
patient at eight hours after the presentation in ED for 
the estimation of the Troponin T level. General 
physical and systemic examination and complete 
history was taken from all participants. Blood samples 
for H-FABP and routine investigations were also 
obtained from the control group.  
Heart-type fatty acid-binding protein was measured 
by using human heart-type fatty acid-binding protein 
(H-FABP) ELISA kit manufactured by Glory 
Biosciences USA for the quantitative determination of 
H-FABP with a detection range of 0.4-22ng/ml. 
The serum samples were stored at -200C until the 
quantitative determination of H-FABP. Samples were 
analyzed in batches with three levels of controls in 
each batch and before analysis, samples were thawed, 
centrifuged and the supernatant was used for analysis. 
Repeated freeze-thaw cycles were avoided.  The 
samples were analyzed according to the 
manufacturer’s instructions. 
Data were analyzed statistically by SPSS software, 
version 18. Quantitative variables were presented as 
mean and standard deviation SD. Qualitative variables 
were presented as frequency and percentages. For the 
comparison of quantitative variables between cases 
and controls independent samples t-test was applied 
while for the comparison of qualitative variables chi-
square test was applied. Sensitivity, specificity, 
positive predictive value (PPV) and negative 
predictive value (NPV) were calculated for H-FABP 
using Trop-T as the gold standard. ROC curve was 
also drawn and AUC was calculated. A p-value ≤ 0.05 
was considered significant. 
 
Results 
 
Two hundred and fifty subjects were included in the 
study. One hundred and twenty-five patients of ACS 
were based on clinical features (±ECG changes) and 
cardiac troponin T. One hundred and twenty-five 
healthy subjects who served as a control group were 
also enrolled in the study. 
The average age of cases was 54.72 years (SD=7.472) 
while the average age of controls was 53 years 
(SD=7.381). The difference in the age of cases and 
controls was insignificant (p=0.068). 
Among cases, there were 99 (79.2%) males and 26 
(20.8%) females. Among controls, there were 87 
(69.6%) males and 38(30.4%) females. There was an 
insignificant difference in gender between cases and 
controls (p=0.082). Both groups were similar with 
respect to age and gender distribution. 
Among cases, the average time duration of symptoms 
was 2.584 hours (SD=0.839) with a minimum duration 
of 1 hour and a maximum duration of 4 hours. Among 
cases, the final diagnosis was STEMI in 73(58.4%), 
NSTEMI in 34(27.2%) and UA in 18(14.4%) cases based 
on Trop-T. Median H-FABP level in cases was 
25.68ng/ml (IQR: 17.78-35.78) with a minimum level 
of 5.62ng/ml and a maximum level of 100.25ng/ml. 
Median H-FABP level in controls was 5.38 ng/ml 
(IQR: 3.78-6.42) with a minimum level of 1.56ng/ml 
and a maximum level of 19.83 ng/ml. H-FABP level 
was significantly higher in cases as compared to 
controls (p ≤ 0.001). Mean H-FABP comparison 
between cases and control is shown (Table-1). 
Using a cut-off value 16ng/ml for H-FABP,91 out of 
125 patients of ACS were correctly diagnosed to have 
acute MI. The sensitivity and specificity of H-FABP in 
diagnosing AMI were 85% and 83.3% respectively at 
this cut-off value (Table-2). The positive predictive 
value (PPV) and negative predictive value (NPV) were 
96.8% and 48.4% respectively. The accuracy of H-
FABP in ACS diagnosis was 84.4% (Table-3).ROC 
curve was drawn and calculated AUC was 0.842 (p ≤ 
0.001, 95% CI: 0.735 – 0.949) (Figure-1). 
 
Table-1: Comparison of mean H-FABP level among 
cases and controls 
 N H – FABP Level 
(ng/ml) 
P-value 
Mean Std. 
Deviation 
Cases 125 28.76 15.77 0.0001 
Controls 125 6.73 4.68 
 
Table-2: Sensitivity & Specificity at the different cut 
off values of H-FABP 
H-FABP level 
(ng/ml) 
Sensitivity Specificity 
7.44 ng/ml 100% 11.1% 
10.89 ng/ml 96.3% 22.2% 
14.78 ng/ml 89.7% 50% 
16 ng/ml 85% 83.3% 
18.94 ng/ml 81.3% 83.3% 
21. ng/ml 70.1% 83.3% 
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Figure-1: ROC curve of H-FABP for the cut-off value 
16ng/ml 
 
Table-3: H-FABP & Trop-T using 16ng/ml as cut-off 
value area under the curve (AUC) 
H-FABP Trop-T Total Area P-
value 
Positive Negative    
Positive 91 3 94 .795 0.0001 
Negative 16 15 31 
Total 107 18 125 
The test result variables: H–FABP Level (ng/ml) has at 
least one tie between the positive actual state group 
and the negative actual state group. 
Sensitivity = 91/107 = 85% 
Specificity = 15/18 = 83.3% 
Positive predictive value (PPV) = 96.8% 
Negative Predictive value (NPV) = 48.4% 
Accuracy = 106/125 = 84.4% 
 
Discussion 
 
Acute coronary syndrome (ACS) is a chief cause of 
morbidity and mortality worldwide. It is strongly 
believed that identification and management of AMI 
at early hours greatly influences the AMI related 
morbidity and mortality and hence it’s related 
expenditure.18 It has also been found that the serum 
levels of cardiac troponins and CK-MB are not 
sufficient to establish the diagnosis of ACS (NSTEMI-
ACS) in the patients seeking urgent medical aid in the 
casualty department within three hours of the onset of 
chest pain. So, for decision making, biomarkers 
facilitating identification of ACS at the initial point of 
time will gain particular significance.19 H-FABP is one 
of the novel biomarkers, which has the potential to re-
enforcing cardiac troponins in the early confirmation 
of AMI.20 At presentation, the combined assessment of 
H-FABP and high-sensitivity troponins (hs-cTn) has 
been proposed as an early rule-out strategy for MI for 
early discharge from ED.21 So far, it has not given 
consistent results as a diagnostic tool for MI, though 
many studies have given excellent results. The main 
reason may be the lack of standardization of its assay 
as different methods are being used for its detection in 
the serum and different researchers have used 
different assays and cut-off values for diagnosis of MI. 
Recently, Vupputuri et al reported the sensitivity of 
89.7%  and specificity 68% for H-FABP in early six 
hours for AMI detection.22 Banuet al have found a 
sensitivity of 25% and AUC of 0.61 in 36 cases 
diagnosed with AMI(both STEMI and NSTEMI) 
presenting within  48 hours of the onset of chest pain 
of which majority presented within four hours. The 
diagnostic cut-off was 7ng/m.23 Ramaiah et al reported 
a sensitivity of 77%, specificity 91% area under ROC 
curve equal to 0.83± 0.05 in ACS patients presenting 
within four hours of symptoms onset by a qualitative 
H-FABP immune-test with a diagnostic cut-off value 
of 10ng/L.24 
The other issue concerned with the fact that some 
studies have not given convincing results may be due 
to the kinetics of H-FABP i.e. early release and rapid 
clearance from plasma, hence having its prime 
diagnostic role in early six hours after which it starts 
declining. It might be the reason for poor results in 
studies in which the patients were included with a 
larger duration of symptoms. The variation in 
performance of H-FABP in ACS diagnosis may also be 
due to several other factors like age group, the gender 
ethnic variations or sample size as this biomarker has 
not been evaluated at a very large scale for 
generalization. Also, the age-specific cut-off values 
have not been established so far. Our study was aimed 
to evaluate the effectiveness of H-FABP in the early 
diagnosis of acute ischemic myocardial damage (AMI) 
in patients with ACS. We have compared H-FABP 
levels with controls to show that H-FABP levels are 
higher in AMI cases. We also established cut-off value 
for H-FABP and the best cut-off level of H-FABP was 
16ng/ml with sensitivity and specificity of 85% and 
83.3% respectively. Our results are consistent with 
many studies where the same method (ELISA) was 
used to analyze H-FABP. 
Our results are consistent with those of Gururajan et al. 
They conducted a case-control study  on 485 subjects 
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including 99 healthy controls and found 87% 
sensitivity and 93% specificity of H-FABP to diagnose 
AMI in patients presenting within four hours of chest 
pain by quantitative ELISA technique keeping a 
diagnostic cut-off level of17.7ng/ml.25 The results of 
our study are also in complete agreement with those of 
Elmadbouh et al who found a diagnostic sensitivity of 
H-FABP 85% and specificity equal to 83.3% within 
three hours of the onset of chest pain by quantitative 
ELISA technique with a diagnostic cut-off of 
21.85ng/ml.16 Our study is further potentiated by 
Cubranic et al who evaluated the performance of H-
FABP and glycogen phosphorylase isozyme BB  in  
AMI diagnosis within three hours after onset of chest 
pain and found that  H-FABP had a sensitivity 99%, 
specificity 99%  by ELISA technique at a cut-off  value 
of 5ng/ml.26 
Similar work was done by Figiel et al.27 They found 
that H-FABP was the most sensitive and accurate 
biomarker among H-FABP, glycogen phosphorylase 
BB (GP-BB) and cTnT in the subgroup presenting in 
the initial three hours of chest pain onset. H-FABP 
gave 79%sensitivity and 100% PPV and an accuracy of 
80% in AMI diagnosis at the 7ng /ml cut-off level. 
Earlier, Pasuoglu et al also assessed 66 patients with 
ACS and found that H-FABP had 100% sensitivity and 
97% specificity and an area of 1.0 under the ROC curve 
in patients presenting within three hours of symptoms 
onset. H-FABP was measured by ELISA with cut-off 
19ng/ml for AMI diagnosis.28 
In our country, a large number of people come to ED 
with chest pain as the main complaint out of which a 
small fraction of cases are with true ACS diagnosis. In 
our study H-FABP at cut-off level, 16ng/ml has 85% 
sensitivity which makes it a better tool to rule out the 
disease at an early phase. The specificity of H-FABP is 
also significant and a more specific test gives a 
minimum number of false-positive results. In our 
study the AUC was equal to 0.842 which confirms that 
the methodology used to analyze H-FABP is good and 
it can discriminate among ACS and non-ACS cases 
efficiently. The positive predictive value which helps 
in confirming ACS was significantly raised which 
shows H-FABP as a useful early diagnostic tool for the 
ischemic type of chest pain in an emergency clinical 
setting.    
 
Conclusion 
  
In conclusion, the measurement of H-FABP is a 
valuable tool in the early diagnosis of patients with 
chest pain (4hrs). H-FABP is a promising biomarker 
for the early detection of ischemic myocardial damage 
(infarction) in patients presenting with the acute 
coronary syndrome and seems to be a preferred 
biomarker in the differential diagnosis of NSTE-ACS. 
More studies are needed to establish the exact role of 
this biomarker in diagnosing ACS at the early phase of 
ischemia. 
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